基因君官网
2015年3月7日讯/生物谷BIOON/–英国医学研究委员会近日宣布，英国将于今年开展首项针对肺癌的干细胞与基因联合治疗的临床试验，受试者是英国国家医疗服务体系（NHS）内的患者。
该试验性治疗将会应用干细胞传递强效的抗癌基因至病灶，诱导癌细胞开启凋亡通路而不损伤正常的组织。据悉，在小鼠试验中，该治疗方法已经表现出可以缩小甚至完全清除肿瘤的功效。
伦敦大学学院的研究团队负责人Sam Janes表示，目前正在志愿者身上开展人体试验，首先是要验证该疗法的安全性，其次将其与标准治疗方式进行有效性的比较。试验过程中，每个患者每隔3周注射3次、大约10亿个细胞（化疗后一天注射）。
Janes表示，一旦临床试验成功，这将会是肺癌治疗的突破性疗法，并且还有应用到其它肿瘤中的前景。
这项试验由英国Biomedical Catalyst提供200万英镑的资助，并且由医学研究理事会和Innovate UK共同管理。医学研究理事会转化医学部门负责人Chris Watkins表示，该项技术的研究有望使英国处于干细胞治疗癌症领域的前沿。(生物谷Bioon.com）
原文 UK will trial stem cell/gene therapy in lung cancer
The first UK clinical trial of a combined stem cell and gene therapy for lung cancer will go ahead with National Health Service patients later this year， the Medical Research Council has confirmed.
The experimental procedure – which uses stem cells to deliver a potent anti-cancer gene that induces a self-destruct pathway in diseased cells， leaving healthy tissues untouched – has been shown to reduce or even clear tumours in early tests with mice.
A research team – led by Sam Janes at UCL/UCLH – will now test the treatment in human volunteers， first to check safety and then efficacy compared with standard care. Each patient in the trial will receive almost a billion cells over three infusions， three weeks apart (injected one day after they receive chemotherapy).
“If clinical trials are successful， our treatment could be transformative for the treatment of lung cancer， and possibly other types of tumour in future，” said Professor Janes， commenting on its potential.
The trial is being funded by a ￡2 million grant from the UK’s Biomedical Catalyst， which is managed jointly by the MRC and Innovate UK. Chris Watkins， Director of Translational Research at the MRC， said the new therapy “is truly at the cutting edge and will draw on the UK’s unique position as a leader in the field of cell-based therapies”.